Education
About Us
Working with TipRanks
Follow Us
Pfizer (PFE)
NYSE:PFE
PFE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.92 - $31.54
Previous CloseN/A
Volume12.20M
Average Volume (3M)44.48M
Market Cap
$132.75B
Enterprise Value$126.67B
Total Cash (Recent Filing)$20.48B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)16.9
Beta0.31
Next Earnings
Aug 05, 2025EPS Estimate
0.57Last Dividend Ex-Date
May 09, 2025Dividend Yield7.27%
Share Statistics
EPS (TTM)0.92
Shares Outstanding5,685,365,700
10 Day Avg. Volume32,256,059
30 Day Avg. Volume44,478,367
Financial Highlights & Ratios
PEG Ratio-7.60
Price to Book (P/B)1.44
Price to Sales (P/S)0.00
P/FCF Ratio13.41
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue0.52
Enterprise Value/Gross Profit3.01
Enterprise Value/Ebitda2.34
Forecast
1Y Price Target
$27.69Price Target Upside18.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
Pfizer News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentSV+pembro achieved notably higher response in PD-L1 TPS ≥50% (100% in n=4 vs 67%), suggesting potential synergy for MMAE ADCs vs TROP2 ADCs in combo with anti-PD(L)1 treatment.
Financial PerformancePfizer's effective cost cuts and better-than-expected COVID products sales have led to 2024 Q4 results beating expectations.
Regulatory ApprovalThe Braftovi combination regimen received FDA accelerated approval as a first-line treatment for BRAF V600E-mutant mCRC.
Bears Say
Clinical Trial ResultsDisappointing results from its oral GLP-1 drug phase 3 clinical trial would result in massive downward earnings revisions as investor sentiment is already cautious.
Drug DevelopmentEfficacy with the go-forward dose of PDL1V monotherapy appears undifferentiated compared to other ADCs in the relapsed/refractory metastatic NSCLC space.
Market CompetitionThere is significant competition in the PD-1/VEGF bispecific antibody market, which could impact the success of PFE's new licensing agreement.
Ownership Overview
0.03% Insiders
16.91% Mutual Funds
12.03% Other Institutional Investors
50.99% Public Companies and Individual Investors
PFE FAQ
What was Pfizer’s price range in the past 12 months?
Pfizer lowest stock price was $20.91 and its highest was $31.54 in the past 12 months.
What is Pfizer’s market cap?
Pfizer’s market cap is $132.75B.
When is Pfizer’s upcoming earnings report date?
Pfizer’s upcoming earnings report date is Aug 05, 2025 which is in 59 days.
How were Pfizer’s earnings last quarter?
Pfizer released its earnings results on Apr 29, 2025. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.666 by $0.254.
Is Pfizer overvalued?
According to Wall Street analysts Pfizer’s price is currently Undervalued.
Does Pfizer pay dividends?
Pfizer pays a Quarterly dividend of $0.43 which represents an annual dividend yield of 7.27%. See more information on Pfizer dividends here
What is Pfizer’s EPS estimate?
Pfizer’s EPS estimate is 0.57.
How many shares outstanding does Pfizer have?
Pfizer has 5,685,365,700 shares outstanding.
What happened to Pfizer’s price movement after its last earnings report?
Pfizer reported an EPS of $0.92 in its last earnings report, beating expectations of $0.666. Following the earnings report the stock price went up 3.183%.
Which hedge fund is a major shareholder of Pfizer?
Currently, no hedge funds are holding shares in PFE
Pfizer Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.69 (18.59% Upside)
$27.69 (18.59% Upside)
Blogger Sentiment
Bullish
PFE Sentiment 91%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 34.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $84.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days >0.1%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.52%
12-Months-Change
Fundamentals
Return on Equity
8.62%
Trailing 12-Months
Asset Growth
-5.91%
Trailing 12-Months
Company Description
Pfizer
Pfizer Inc. (PFE) is a leading global biopharmaceutical company headquartered in New York City. The company is dedicated to the discovery, development, manufacturing, and marketing of prescription medicines for humans and animals. Pfizer's core products span multiple therapeutic areas, including vaccines, oncology, inflammation and immunology, rare diseases, internal medicine, and hospital products. With a strong presence in both developed and emerging markets, Pfizer is committed to advancing health and wellness through innovative healthcare solutions.
PFE Company Deck
PFE Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Pfizer's earnings call highlighted a strong R&D pipeline and strategic focus on growth areas such as oncology and cardiometabolic segments, alongside significant growth in key products. However, the company also faced challenges, including a decline in overall revenue and potential impacts from global trade uncertainties and competition. Despite these challenges, Pfizer demonstrated strong operational efficiency and cost management, positioning itself for future growth.Read More>PFE Revenue Breakdown
47.36% Primary Care
26.17% Specialty Care
24.54% Oncology
1.80% PFIZER CENTREONE
0.13% PFIZER IGNITE
PFE Stock 12 Month Forecast
Average Price Target
$27.69
▲(18.59%Upside)